After six month decline, stock plummets on disappointing guidance... Invitrogen is known as an aggressive player. It makes its presence felt at every meeting and trade show in the country. It recently acquired BioReliance and credited that acquisition for boosting its BioProduction revenue by 53%. The acquisition of Molecular Probes led to a 19% growth in its BioDiscovery business according to the Company. Overall revenue came in at $254MM, up 32% from a year ago. But that couldn’t save it from disappointing guidance. The stock that traded as high as $82.00 in February of this year is now down below $52/share.
